1887

Abstract

The epitope for a human papillomavirus (HPV) type 6 conformation-dependent, neutralizing monoclonal antibody (mAb) was partially mapped using HPV L1 recombinant virus-like particles (VLPs). The mAb H6.J54 is cross-reactive with the closely related HPV types 6 and 11. By making HPV-6-like amino acid substitutions in the cottontail rabbit papillomavirus (CRPV) major capsid protein L1, we were able to transfer H6.J54 binding activity into a CRPV/HPV-6 hybrid L1 protein. Full binding activity was achieved with only nine amino acid changes and identified a region centred on the HPV-6 residues 49–54. This region has previously been shown to be a critical part of HPV-6 type-specific epitopes. Fine mapping of the region by scanning a series of alanine substitution mutations showed that in HPV-6 VLPs this type-common epitope overlaps HPV-6 type-specific epitopes.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.18872-0
2003-06-01
2024-03-28
Loading full text...

Full text loading...

/deliver/fulltext/jgv/84/6/vir841493.html?itemId=/content/journal/jgv/10.1099/vir.0.18872-0&mimeType=html&fmt=ahah

References

  1. Bauer H. M., Ting Y., Greer C. E., Chambers J. C., Tashiro C. J., Chimera J., Reingold A., Manos M. M. 1991; Genital human papillomavirus infection in female university students as determined by a PCR-based method [see comments]. JAMA 265:472–477
    [Google Scholar]
  2. Benincasa D., Silberklang M., Mark G. E. III., Ludmerer S. W. 1996; Rapid, high-level transient expression of papillomavirus-like particles in insect cells. Biotechniques 20:890–895
    [Google Scholar]
  3. Bosch F. X., Manos M. M., Munoz N. 7 other authors 1995; Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group [see comments]. J Natl Cancer Inst 87:796–802
    [Google Scholar]
  4. Breitburd F., Kirnbauer R., Hubbert N. L., Nonnenmacher B., Trin Dinh Desmarquet C., Orth G., Schiller J. T., Lowy D. R. 1995; Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 69:3959–3963
    [Google Scholar]
  5. Brown D. R., Bryan J. T., Schroeder J. M. 8 other authors 2001; Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlation with competitive radioimmunoassay titer. J Infect Dis 184:1183–1186
    [Google Scholar]
  6. Bryan J. T., Jansen K. U., Lowe R. S., Fife K. H., McClowry T., Glass D., Brown D. R. 1997; Human papillomavirus type 11 neutralization in the athymic mouse xenograft system: correlation with virus-like particle IgG concentration. J Med Virol 53:185–188
    [Google Scholar]
  7. Chackerian B., Lowy D. R., Schiller J. T. 1999; Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles. Proc Natl Acad Sci U S A 96:2373–2378
    [Google Scholar]
  8. Chen X. S., Garcea R. L., Goldberg I., Casini G., Harrison S. C. 2000; Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell 5:557–567
    [Google Scholar]
  9. Christensen N. D., Kreider J. W. 1991; Neutralization of CRPV infectivity by monoclonal antibodies that identify conformational epitopes on intact virions. Virus Res 21:169–179
    [Google Scholar]
  10. Christensen N. D., Kirnbauer R., Schiller J. T., Ghim S. J., Schlegel R., Jenson A. B., Kreider J. W. 1994; Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes. Virology 205:329–335
    [Google Scholar]
  11. Christensen N. D., Dillner J., Eklund C., Carter J. J., Wipf G. C., Reed C. A., Cladel N. M., Galloway D. A. 1996a; Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology 223:174–184
    [Google Scholar]
  12. Christensen N. D., Reed C. A., Cladel N. M., Hall K., Leiserowitz G. S. 1996b; Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6. Virology 224:477–486
    [Google Scholar]
  13. Christensen N. D., Reed C. A., Cladel N. M., Han R., Kreider J. W. 1996c; Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J Virol 70:960–965
    [Google Scholar]
  14. Christensen N. D., Cladel N. M., Reed C. A., Budgeon L. R., Embers M. E., Skulsky D. M., McClements W. L., Ludmerer S. W., Jansen K. U. 2001; Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types. Virology 291:324–334
    [Google Scholar]
  15. Evans T. G., Bonnez W., Rose R. C. 8 other authors 2001; A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. J Infect Dis 183:1485–1493
    [Google Scholar]
  16. Galloway D. A. 1994; Human papillomavirus vaccines: a warty problem. Infect Agents Dis 3:187–193
    [Google Scholar]
  17. Gissmann L., Wolnik L., Ikenberg H., Koldovsky U., Schnurch H. G., zur Hausen H. 1983; Human papillomavirus types 6 and 11 DNA sequences in genital and laryngeal papillomas and in some cervical cancers. Proc Natl Acad Sci U S A 80:560–563
    [Google Scholar]
  18. Harro C. D., Pang Y. Y., Roden R. B. 10 other authors 2001; Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 93:284–292
    [Google Scholar]
  19. Heino P., Skyldberg B., Lehtinen M., Rantala I., Hagmar B., Kreider J. W., Kirnbauer R., Dillner J. 1995; Human papillomavirus type 16 capsids expose multiple type-restricted and type-common antigenic epitopes. J Gen Virol 76:1141–1153
    [Google Scholar]
  20. Ho G. Y., Bierman R., Beardsley L., Chang C. J., Burk R. D. 1998; Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 338:423–428
    [Google Scholar]
  21. Hofmann K. J., Cook J. C., Joyce J. G., Brown D. R., Schultz L. D., George H. A., Rosolowsky M., Fife K. H., Jansen K. U. 1995; Sequence determination of human papillomavirus type 6a and assembly of virus-like particles in Saccharomyces cerevisiae . Virology 209:506–518
    [Google Scholar]
  22. Jansen K. U., Rosolowsky M., Schultz L. D., Markus H. Z., Cook J. C., Donnelly J. J., Martinez D., Ellis R. W., Shaw A. R. 1995; Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation. Vaccine 13:1509–1514
    [Google Scholar]
  23. Kirnbauer R., Booy F., Cheng N., Lowy D. R., Schiller J. T. 1992; Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A 89:12180–12184
    [Google Scholar]
  24. Kirnbauer R., Taub J., Greenstone H., Roden R., Durst M., Gissmann L., Lowy D. R., Schiller J. T. 1993; Efficient self-assembly of human papillomavirus type 16 L1 and L1–L2 into virus-like particles. J Virol 67:6929–6936
    [Google Scholar]
  25. Kirnbauer R., Chandrachud L. M., O'Neil B. W. 7 other authors 1996; Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology 219:37–44
    [Google Scholar]
  26. Koutsky L. A., Ault K. A., Wheeler C. M., Brown D. R., Barr E., Alvarez F. B., Lupinacci L. C., Jansen K. U. 2002; Randomized clinical trial of human papillomavirus type 16 vaccine. New Engl J Med 347:645–651
    [Google Scholar]
  27. Lowe R. S., Brown D. R., Bryan J. T. 11 other authors 1997; Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast. J Infect Dis 176:1141–1145
    [Google Scholar]
  28. Ludmerer S. W., McClements W. L. 1999; Humoral responses to human papillomaviruses that neutralize infectivity. Curr Top Virol 1:169–174
    [Google Scholar]
  29. Ludmerer S. W., Benincasa D., Mark G. E. III 1996; Two amino acid residues confer type specificity to a neutralizing, conformationally dependent epitope on human papillomavirus type 11. J Virol 70:4791–4794
    [Google Scholar]
  30. Ludmerer S. W., Benincasa D., Mark G. E. III, Christensen N. D. 1997; A neutralizing epitope of human papillomavirus type 11 is principally described by a continuous set of residues which overlap a distinct linear, surface-exposed epitope. J Virol 71:3834–3839
    [Google Scholar]
  31. Ludmerer S. W., McClements W. L., Wang X. M., Ling J. C., Jansen K. U., Christensen N. D. 2000; HPV11 mutant virus-like particles elicit immune responses that neutralize virus and delineate a novel neutralizing domain. Virology 266:237–245
    [Google Scholar]
  32. McClements W. L., Wang X. M., Ling J. C., Skulsky D. M., Christensen N. D., Jansen K. U., Ludmerer S. W. 2001; A novel human papillomavirus type 6 neutralizing domain comprising two discrete regions of the major capsid protein L1. Virology 289:262–268
    [Google Scholar]
  33. Moscicki A. B., Hills N., Shiboski S. 9 other authors 2001; Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 285:2995–3002
    [Google Scholar]
  34. Munoz N. 2000; Human papillomavirus and cancer: the epidemiological evidence. J Clin Virol 19:1–5
    [Google Scholar]
  35. Neeper M. P., Hofmann K. J., Jansen K. U. 1996; Expression of the major capsid protein of human papillomavirus type 11 in Saccharomyces cerevisae . Gene 180:1–6
    [Google Scholar]
  36. Pastrana D. V., Vass W. C., Lowy D. R., Schiller J. T. 2001; NHPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16. Virology 279:361–369
    [Google Scholar]
  37. Pisani P., Parkin D. M., Ferlay J. 1993; Estimates of the worldwide mortality from eighteen major cancers in; 1985; Implications for prevention and projections of future burden. Int J Cancer 55:891–903
    [Google Scholar]
  38. Roden R. B., Armstrong A., Haderer P., Christensen N. D., Hubbert N. L., Lowy D. R., Schiller J. T., Kirnbauer R. 1997; Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope. J Virol 71:6247–6252
    [Google Scholar]
  39. Rose R. C., Bonnez W., Reichman R. C., Garcea R. L. 1993; Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles. J Virol 67:1936–1944
    [Google Scholar]
  40. Rose R. C., Reichman R. C., Bonnez W. 1994; Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera. J Gen Virol 75:2075–2079
    [Google Scholar]
  41. Slupetzky K., Shafti Keramat S., Lenz P., Brandt S., Grassauer A., Sara M., Kirnbauer R. 2001; Chimeric papillomavirus-like particles expressing a foreign epitope on capsid surface loops. J Gen Virol 82:2799–2804
    [Google Scholar]
  42. Suzich J. A., Ghim S. J., Palmer Hill F. J., White W. I., Tamura J. K., Bell J. A., Newsome J. A., Jenson A. B., Schlegel R. 1995; Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A 92:11553–11557
    [Google Scholar]
  43. Volpers C., Schirmacher P., Streeck R. E., Sapp M. 1994; Assembly of the major and the minor capsid protein of human papillomavirus type 33 into virus-like particles and tubular structures in insect cells. Virology 200:504–512
    [Google Scholar]
  44. Yeager M. D., Aste Amezaga M., Brown D. R. 9 other authors 2000; Neutralization of human papillomavirus (HPV) pseudovirions: a novel and efficient approach to detect and characterize HPV neutralizing antibodies. Virology 278:570–577
    [Google Scholar]
  45. Zhou J., Sun X. Y., Stenzel D. J., Frazer I. H. 1991; Expression of vaccinia recombinant HPV-16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 185:251–257
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.18872-0
Loading
/content/journal/jgv/10.1099/vir.0.18872-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error